Vitamin K2 ingredient supplier Kappa Bioscience has formed a scientific and medical advisory board “to support and expand the scientific knowledge base for vitamin K2,” including the firm’s branded ingredient K2Vital.
Vitamin K2 ingredient supplier Kappa Bioscience (Oslo, Norway) has formed a scientific and medical advisory board “to support and expand the scientific knowledge base for vitamin K2,” such as the firm’s branded ingredient K2Vital.
“The board reflects Kappa's unique commitment to growing awareness of the rapidly expanding range of benefits associated with vitamin K2 in the form of menaquinone 7 (MK-7),” it said in a press release. “It will include world authorities in relevant fields of science, including cardiology, immunology, kinesiology, and molecular nutrition, and will set a new standard for the scientific support and advancement of emerging nutritional compounds.”
The board has already added the following researchers:
More members will be announced soon. The group will be led by Trygve Bergeland, PhD, Kappa’s vice president of science.
“The formation of Kappa's Scientific and Medical Advisory Board is a further demonstration of the company's commitment to maintaining its leadership position in the K2 sector and to bringing its remarkable health benefits to a growing number of consumers worldwide,” stated Egil Greve, Kappa's CEO, in a press release. “We are honored to have attracted this esteemed group of scientists. The top-class experts together have authored over 700 scientific papers. We are confident that with their help, awareness of vitamin K2 and its scope of benefits will rapidly accelerate.”
HHS announces restructuring plans to consolidate divisions and downsize workforce
Published: March 27th 2025 | Updated: March 27th 2025According to the announcement, the restructuring will save taxpayers $1.8 billion per year by reducing the workforce by 10,000 full-time employees and consolidating the department’s 28 divisions into 15 new divisions.